Pharmaron Beijing Co., Ltd. (SHE:300759)
China
· Delayed Price · Currency is CNY 27.11
-0.24 (-0.88%)
Mar 10, 2026, 9:25 AM CST
Pharmaron Beijing Revenue
Pharmaron Beijing had revenue of 3.64B CNY in the quarter ending September 30, 2025, with 13.44% growth. This brings the company's revenue in the last twelve months to 13.54B, up 14.83% year-over-year. In the year 2024, Pharmaron Beijing had annual revenue of 12.28B with 6.39% growth.
Revenue (ttm)
13.54B
Revenue Growth
+14.83%
P/S Ratio
3.39
Revenue / Employee
633.79K
Employees
22,908
Market Cap
45.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12.28B | 737.78M | 6.39% |
| Dec 31, 2023 | 11.54B | 1.27B | 12.39% |
| Jan 1, 2023 | 10.27B | 2.82B | 37.92% |
| Dec 31, 2021 | 7.44B | 2.31B | 45.00% |
| Dec 31, 2020 | 5.13B | 1.38B | 36.64% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Allist Pharmaceuticals | 5.17B |
| Beijing Wantai Biological Pharmacy Enterprise | 1.80B |
| Shanghai RAAS Blood Products | 7.95B |
| Haisco Pharmaceutical Group | 4.27B |
| Hebei Changshan Biochemical Pharmaceutical | 928.01M |
| Chongqing Zhifei Biological Products | 10.91B |
| Sunshine Guojian Pharmaceutical (Shanghai) | 4.20B |
| Asymchem Laboratories (Tianjin) | 6.29B |